750386
Last Update Posted: 2011-05-23
Recruiting has ended
Females accepted | 18 Years-75 Years |
50 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas
This trial will determine the feasibility and toxicity of dose intense (every 2 weeks) of paclitaxel+carboplatin combination following cytoreductive surgery in patients with stage Ic-IV ovarian cancer.
Dose dense chemotherapy has been proven beneficial in various oncological settings. It is proposed that this concept be tested in ovarian cancer, with the support of growth factors. It is hypothesized that, if feasible, dose-dense chemotherapy may be more effective.
Eligibility
Relevant conditions:
Ovarian Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov